FPI-2265 showed promising activity in patients with metastatic castration-resistant prostate cancer which was similar to prior safety and efficacy data reported.
So-called "right-to-try" is a cruel sham that holds out the mostly false hope of survival to terminally ill patients and their families. In return, all they have to give up is patient protections and agree to pay to be guinea pigs to test a drug company's product. The product of an ideology that uses the terminally ill as shields to hide the ideological motives behind the law, which are to hobble the FDA, right-to-try is a terrible idea. It's bad for patients, but it just passed the Senate and could well become the law of the land when the House reconvenes in September if it isn't stopped.
/PRNewswire/ Fusion Pharmaceuticals Inc. (Nasdaq: FUSN) ("Fusion"), a clinical-stage oncology company focused on developing next-generation targeted alpha.
Fusion Pharmaceuticals (FUSN) Announces 17 6M Share Offering at $3 40/sh, Acquires Phase 2 Program for 225Ac-PSMA I&T streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
New ‘nomogram’ opens the door to improved personalized treatments, UCLA-led study shows
UCLA
Based on the study, researchers also created an online risk calculator that forecasts the probability of overall and progression-free survival in response to LuPSMA. Denise Heady |
July 8, 2021
A new prognostic tool developed by researchers from the UCLA Jonsson Comprehensive Cancer Center and five other institutions helps predict which men with advanced metastatic prostate cancer will respond favorably to a novel targeted therapy.
The tool, described in a study published today in Lancet Oncology, analyzes a wide spectrum of imaging and clinical data and is intended to assist physicians considering treating patients with Lutetium-177 prostate-specific membrane antigen, or LuPSMA.